Kirin

LC-Plasma-based Vaccine Research Selected for SCARDA Project

Retrieved on: 
Mercoledì, Maggio 8, 2024
Health, Infectious Diseases, Other Health, Research, Science, Pharmaceutical, Biotechnology, Infection, Kirin Holdings, Christian democracy, Postbiotic, Holding company, SARS-CoV-2, Bacteria, Plasma, Vaccine, Urinary tract infection, Immunization, Research and development, Virus, Kirin, Medical research, Multimedia, AMED, BBRC

We now announce that a proposal for our collaborative research has currently been accepted as a project for research and development into new modalities contributing to vaccine development by the Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) in the Japan Agency for Medical Research and Development (AMED).

Key Points: 
  • We now announce that a proposal for our collaborative research has currently been accepted as a project for research and development into new modalities contributing to vaccine development by the Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) in the Japan Agency for Medical Research and Development (AMED).
  • View the full release here: https://www.businesswire.com/news/home/20240507111790/en/
    This research aims at developing an intranasal LC-Plasma vaccine to induce innate immunity for prevention of respiratory virus infection.
  • SCARDA was established at AMED in March, 2022, based on the national strategy, to strengthen strategic research funding and to promote the formation of world-class research and development centers ( https://www.amed.go.jp/en/program/list/21/index.html ).
  • This project is to explore the potential of intranasal LC-Plasma vaccination to prevent respiratory infection with viruses including SARS-CoV-2 and influenza viruses.

Kirin Group chooses Board, the leader in Intelligent Planning, to complete its financial transformation

Retrieved on: 
Giovedì, Dicembre 14, 2023
Technology, Finance, Consulting, Fintech, Other Technology, Professional Services, Software, Data Management, Other Professional Services, Kirin Holdings, Drink, FP&A, Strategic planning, Kirin, Intelligence, Finance department, Punjab (Pakistan), Go go, Ministry of Finance, Economic Development Board, Management, Food, Medication

Kirin Group is known for globally recognized products including Kirin ICHIBAN and Gogo-no-Kocha.

Key Points: 
  • Kirin Group is known for globally recognized products including Kirin ICHIBAN and Gogo-no-Kocha.
  • In 2021, Kirin Holding built a new team to lead corporate FP&A efforts and effectively drive the group's long-term strategic planning.
  • Board appears to be the right solution to complete Kirin’s financial transformation.
  • Our FP&A efforts will contribute to our company’s further growth"
    “We are delighted to support Kirin’s Financial transformation with our proven Intelligent Planning Solutions.

Kirin iMUSE Immune Care and Healthya Visceral Fat Down will go on sale on Tuesday, November 28!

Retrieved on: 
Lunedì, Novembre 27, 2023
Retail, Health, Fitness & Nutrition, General Health, Vitamins, Supplements, Food, Beverage, Biotechnology, Sale, Capsule, PubMed, Lactococcus lactis, Immunity, Research, Immune system, Kao Corporation, Plasma, Coffee, Government, Polyphenol, Multimedia, Christian democracy, Consumer Affairs Agency, Kirin, Invention, University, BMI, Imperial, Kirin Holdings, IMUSE, Human, Lipid metabolism, Growth, Holding company, Chlorogenic acid, Vaccine, Dietary supplement, Medical device

Kirin Holdings Company, Limited (TOKYO:2503) will launch a dual-care functional food supplement Kirin iMUSE Immuno-Care and Healthya Visceral Fat Down on November 28 (Tuesday).

Key Points: 
  • Kirin Holdings Company, Limited (TOKYO:2503) will launch a dual-care functional food supplement Kirin iMUSE Immuno-Care and Healthya Visceral Fat Down on November 28 (Tuesday).
  • This product is a collaboration between Kirin iMUSE, Japan’s first*1 immune care brand, and Kao Healthya, Japan’s first*1 body fat care beverage brand from Kao Corporation (TOKYO:4452), and will be sold at drugstores nationwide and through Kirin Kyowa Hakko Bio mail order.
  • We are developing a broad lineup of functional food products with immune function claims to help customers solve their health issues.
  • “Kirin iMUSE Immunity Care and Healthya Visceral Fat Down,” which is about to go on sale, is a product born from the joint research project.

Japan’s First Discovery*1 on Visceral Fat and Immune Activity in Joint Research by Kirin Holdings and Kao

Retrieved on: 
Venerdì, Novembre 24, 2023
COVID-19, Research, Infectious Diseases, Fitness & Nutrition, Other Health, General Health, University, Health, Science, Education, World Health Organization, Odds ratio, Atherosclerosis, Obesity, Immunity, Coronavirus, Conditional sentence, Ageing, Incidence, Atrophy, WHO, Risk, Journal, Facial muscles, Kirin, Kirin Holdings, Wakayama Medical University, Blood, Vaccine, Pharmaceutical industry, Dietary supplement, PDC, PubMed

Visceral fat area: Based on a median value of 77 cm2 for all subjects, those with visceral fat less than 77 cm2 were defined as the low visceral fat group, and those with visceral fat greater than 77 cm2 as the high visceral fat group.

Key Points: 
  • Visceral fat area: Based on a median value of 77 cm2 for all subjects, those with visceral fat less than 77 cm2 were defined as the low visceral fat group, and those with visceral fat greater than 77 cm2 as the high visceral fat group.
  • For the first time in the world, this collaboration found that people with high visceral fat area levels had low pDC activity.
  • It was also suggested that visceral fat area and pDC activity, respectively, affect susceptibility to novel coronavirus infection and influenza, and that people with high visceral fat area and low pDC activity are particularly susceptible to these diseases.
  • Thus, it can be said that it is important for people with high visceral fat area values and low pDC activity to address both visceral fat mass and immune function.

Kyowa Kirin to Acquire Orchard Therapeutics

Retrieved on: 
Giovedì, Ottobre 5, 2023
Acquisition, HSC, Therapy, Stem cell, Vision, Health, Research, Priority review, Morrison, Sanfilippo syndrome, Food and Drug Administration Amendments Act of 2007, DSM-IV codes, Kyowa Kirin, Frontotemporal dementia, EC, JST, MLD, Civil service commission, Health care, Food, European Commission, Biotechnology, Transaction, FDA, CVR, FTD, MPS, Guggenheim Partners, Kirin, Sanfilippo, TSE, ADS, MHRA, Morrison & Foerster, Science, PDUFA, Life, Patient, Communications satellite, Pharmaceutical industry, Vaccine, Security (finance), Orchard, Atidarsagene autotemcel

TOKYO and LONDON and BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company (J-GSP) creating innovative medical solutions utilizing the latest biotechnology, and Orchard Therapeutics plc (Orchard Therapeutics, Nasdaq: ORTX), a global gene therapy leader, today announced the companies have entered into a definitive agreement under which Kyowa Kirin will acquire Orchard Therapeutics for $16.00 per American Depositary Share (ADS) in cash (approximately $387.4 million, or ¥57.3 billion), under which Orchard shareholders will hold an additional contingent value right (CVR) of $1.00 per ADS. An additional $1.00 CVR will be paid for a total of $17.00 per ADS, or approximately $477.6 million (¥70.7 billion) if the conditions are met.

Key Points: 
  • Kyowa Kirin has established a 2030 Vision to consistently create and deliver medicines with life-changing value that ultimately makes people smile, as a J-GSP.
  • “We are excited to announce that we have signed the Transaction Agreement to acquire Orchard Therapeutics, one of the leading providers of HSC gene therapy,” said Takeyoshi Yamashita, Ph.D., Director of the Board, chief medical officer, senior managing executive officer of Kyowa Kirin.
  • Under the terms of the agreement, Kyowa Kirin will initiate a scheme of arrangement to acquire all Orchard Therapeutics’ ADSs at a price of $16.00 per ADS in cash (or aggregated value of approximately $387.4 million, or approximately ¥57.3 billion) at closing, which represents a premium of 144% to Orchard Therapeutics’ volume-weighted average price per ADS over the previous 30 days ended October 4.
  • Following the completion of the acquisition, Orchard Therapeutics will become a wholly-owned subsidiary of Kyowa Kirin.

Revolutionizing Cockpit Entertainment: Unveiling 2023 Passenger Car Trends and Innovations - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Settembre 11, 2023
Technology, Electronic Games, Vehicle Technology, Automotive, Entertainment, General Automotive, Other Automotive, Software, Hardware, Consumer Electronics, Atmos, Aion, Cloud, LED-backlit LCD, Data center, FM, Social, AMD, Smartphone, Music, Kirin, Original equipment manufacturer, IVI, Model, Human, BYD, Qualcomm, NIO, HDR, QQ Music, XPeng, Cisco Webex, WeChat, GeForce, BMW, BMW 5 Series, AAA, Business model, NVIDIA, OLED, AirConsole, KuGou, Computer, Zoom, Ecosystem, OEM, Tesla, Tesla Model S, Dolby Atmos, GeForce Now, AR, Steam, Li Auto, Mercedes-Benz COMAND, Amusement park, Video game, Nvidia

The "Passenger Car Cockpit Entertainment Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Passenger Car Cockpit Entertainment Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.
  • The Passenger Car Cockpit Entertainment Research Report for 2023 explores the landscape of cockpit entertainment function layouts within passenger car original equipment manufacturers (OEMs) and cockpit entertainment product layouts among suppliers.
  • The report provides insights into the current state of cockpit entertainment development and predicts future trends in this field.
  • In conclusion, the evolution of cockpit entertainment is entering a new phase, focusing on immersive scenarios such as gaming.

SUIC and I H Art Group, Authorized Distributor of Heineken & Kirin, With 2 New Stores in Hong Kong and Macau 5-Star Casino, Join Hands With Catering Groups to Develop 25 Brands, Over 300 Stores to Enter the US

Retrieved on: 
Mercoledì, Settembre 6, 2023
BBQ, IPO, Marketing, Wall Street, OTC, Growth, Family, Fast food, Kirin, James A. Beneway High School, Heineken

SUIC and I H Art Group form strategic alliances with various catering groups to develop 25 brands and 300 stores to enter into US.

Key Points: 
  • SUIC and I H Art Group form strategic alliances with various catering groups to develop 25 brands and 300 stores to enter into US.
  • I H Art Group is currently operating 150 global franchised locations under a variety of brands and products in its portfolio including hot pot, Monga Taiwan style fried chicken, flower tea drinks, dumplings, cloud kitchen management, AI Smart machines, and more.
  • “SUIC and I H Art Group adopt a revolutionary multi-branding cuisine-specific business model that offers customers a wide variety of brand choices under one roof without diminishing brand equity, as opposed to just a single brand.
  • It is a key growth driver in the competitive food market that we are expanding from Taiwan and Asia into the US and Europe,” said Hank Wang, CEO.

Beyond the Steering Wheel: Passenger Car Cockpit Entertainment Evolution Explored in 2023 Report

Retrieved on: 
Venerdì, Settembre 1, 2023
Atmos, Aion, Cloud, LED-backlit LCD, Data center, FM, Social, AMD, Smartphone, Music, Kirin, Software, Original equipment manufacturer, IVI, Model, Human, BYD, Qualcomm, NIO, HDR, QQ Music, XPeng, Cisco Webex, WeChat, GeForce, BMW, BMW 5 Series, AAA, Business model, NVIDIA, OLED, AirConsole, KuGou, Computer, Delivery, Zoom, Ecosystem, OEM, Tesla, Tesla Model S, Dolby Atmos, GeForce Now, AR, Steam, Li Auto, Mercedes-Benz COMAND, Amusement park, Video game, Nvidia

DUBLIN, Sept. 1, 2023 /PRNewswire/ -- The "Passenger Car Cockpit Entertainment Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 1, 2023 /PRNewswire/ -- The "Passenger Car Cockpit Entertainment Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.
  • The Passenger Car Cockpit Entertainment Research Report for 2023 explores the landscape of cockpit entertainment function layouts within passenger car original equipment manufacturers (OEMs) and cockpit entertainment product layouts among suppliers.
  • The report provides insights into the current state of cockpit entertainment development and predicts future trends in this field.
  • In conclusion, the evolution of cockpit entertainment is entering a new phase, focusing on immersive scenarios such as gaming.

Herencia Artifex, an NFT project for artistic collaboration across genres, sells the first of NFT

Retrieved on: 
Giovedì, Maggio 25, 2023
Nail, NFT, Web3, Exhibition, HXA, Buddhism, Sale, Kirin, Cryptocurrency, OpenSea

This genre-transcending artistic collaboration in the Web3 space will give birth to new art forms and expressions, contributing to enriching the field of art.

Key Points: 
  • This genre-transcending artistic collaboration in the Web3 space will give birth to new art forms and expressions, contributing to enriching the field of art.
  • The first NFT "Gizan Katoh" is a collaboration with Gizan Kato, a Buddhist priest and the main artist of the exhibition, and is based on his work "Kirin" (Qilin).
  • Kirin" is a phantom animal said to bring good fortune and to appear in a peaceful world in Japan.
  • In addition to NFT, we will also be developing a realistic art collaboration with Gisan Kato.

Nagasaki University Presented Results Of a Specified Clinical Trial On The Use of L. lactis strain Plasma For Patients With COVID-19

Retrieved on: 
Giovedì, Maggio 11, 2023
Science, Research, Pharmaceutical, Health, COVID-19, University, Education, Clinical Trials, Vaccine, First Department, Smell, Kirin Holdings, Food, Anosmia, Rotavirus, Shortness, Headache, SARS-CoV-2, PDC, Consumer Affairs Agency, Clinical trial, Infection, Division, Multimedia, Chest pain, Fatigue, Lactococcus lactis, Pandemic, Patient, Patent, Risk, Fever Dream, Immune system, Internal medicine, Randomized controlled trial, Blood, Viral load, Shortness of breath, Nagasaki University, Cough, Respiratory Medicine, Institute for Plasma Research, Safety, Pharmaceutical industry, Copper, Omicron, Kirin, Anorexia nervosa, Dysgeusia, Limited, Immunity, Lactococcus, Plasma

Nagasaki University presented the results of a specified clinical trial on patients with COVID-19 using Lactococcus.

Key Points: 
  • Nagasaki University presented the results of a specified clinical trial on patients with COVID-19 using Lactococcus.
  • lactis strain Plasma*1 (L.lactis Plasma, a postbiotic), researched and developed by Kirin Holdings Company, Limited (Kirin Holdings).
  • Nagasaki University and Kirin Holdings have jointly filed a patent application for the findings of this specified clinical trial.
  • Nagasaki University and Kirin hope that L. lactis Plasma will become one of the new treatment or adjunctive care to patients with mild COVID-19.